Why Bb Biotech Ag Reported Agios Pharmaceuticals Inc Position?

February 15, 2018 - By Adrian Mccoy

 Why Bb Biotech Ag Reported Agios Pharmaceuticals Inc Position?

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.83, from 2.04 in 2017Q2. It worsened, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported.

Blackrock Inc reported 2.87 million shares. Ray Gerald L & Associate Limited accumulated 29,465 shares. Opaleye Management Inc invested in 130,000 shares. Fernwood Investment Management Limited Liability reported 27,850 shares stake. Manufacturers Life The holds 1,465 shares or 0% of its portfolio. One Trading Lp owns 23,055 shares. Loomis Sayles & Company Ltd Partnership reported 0.03% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Weiss Multi stated it has 0.02% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Oppenheimer Asset Mngmt Inc, a New York-based fund reported 37 shares. Spark Ltd holds 0.18% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 49,200 shares. Jennison Assocs Limited Liability invested in 0.01% or 166,065 shares. The Georgia-based Voya Inv Management Limited Liability has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Profund Advsr Limited Liability Company invested 0.05% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Swiss State Bank reported 68,460 shares or 0.01% of all its holdings. Sg Americas Secs Ltd Company holds 0% or 7,625 shares.

Since August 22, 2017, it had 0 insider purchases, and 22 sales for $25.02 million activity. On Monday, September 11 the insider Biller Scott sold $975,000. Bowden Christopher also sold $390,000 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, September 11. $284,380 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Cantley Lewis Clayton Jr.. Hoerter Steven L. also sold $1.87M worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. The insider Alenson Carman sold $161,250.

The New Bb Biotech Ag Holding in Agios Pharmaceuticals Inc

Bb Biotech Ag reported SC 13G/A form with the SEC for Agios Pharmaceuticals Inc. Access it here: 000119312518045481. As reported by Bb Biotech Ag, the filler owns 5.6% or 2,719,998 shares of the Health Care–company.

Agios Pharmaceuticals Inc stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Bb Biotech Ag’s positive view for Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc Institutional Sentiment

Filings show 143 investors own Agios Pharmaceuticals Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 10619535. 40444058 were owned by these investors. 25 funds opened new Agios Pharmaceuticals Inc stakes, 58 increased positions. There were 31 that closed positions and 44 reduced them.

2 investors had the stock in their top 10. Some are: Bb Biotech Ag, Opaleye Management Inc…

Opus Point Partners Management Llc is an investor bullish on Agios Pharmaceuticals Inc, owning 46000 shares as of Q3 2015 for 1.79% of its portfolio. Parametrica Management Ltd owns 4866 shares or 2.16% of its portfolio. MA Flagship Ventures 2007 General Partner Llc have 85.66% of its portfolio for 1930369 shares. Further, Bb Biotech Ag reported stake worth 4.72% of its portfolio. The MA S&Co Inc owns 3400 shares. Agios Pharmaceuticals Inc is 0.04% of its portfolio.

Business Profile

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

SEC Form 13G.

The stock increased 1.01% or $0.79 during the last trading session, reaching $78.76. About 260,611 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since February 15, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.52 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals has $132 highest and $47 lowest target. $75.64’s average target is -3.96% below currents $78.76 stock price. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, November 9 by Roth Capital. The rating was initiated by BTIG Research with “Neutral” on Friday, August 19. The firm earned “Buy” rating on Tuesday, June 6 by Cowen & Co. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Neutral” rating by Janney Capital on Wednesday, March 2. The rating was downgraded by Leerink Swann to “Market Perform” on Monday, December 7. The firm has “Buy” rating given on Wednesday, May 18 by Suntrust Robinson. The stock has “Buy” rating by Oppenheimer on Thursday, June 1. The rating was maintained by SunTrust on Sunday, November 19 with “Buy”. The firm earned “Buy” rating on Sunday, June 11 by Oppenheimer. As per Tuesday, August 8, the company rating was maintained by Oppenheimer.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Nasdaq.com which released: “Here’s Why Agios (AGIO) Stock is Up More Than 50% in a Year” on January 19, 2018, also Globenewswire.com with their article: “Agios Announces Closing of Public Offering and Full Exercise of Option to …” published on January 23, 2018, Streetinsider.com published: “Agios Pharma (AGIO) Says FDA Accepted NDA and Granted Priority Review for …” on February 15, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Globenewswire.com and their article: “Agios Reports Fourth Quarter and Full Year 2017 Financial Results” published on February 14, 2018 as well as Nasdaq.com‘s news article titled: “Agios Pharmaceuticals (AGIO) Q4 Earnings: What’s in Store?” with publication date: February 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: